x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Oncology News Central Peer-Spectives

Oncololgy News Central

Peer-Spectives is a podcast series that is moderated by Robert Figlin, MD, and features various oncology thought-leaders covering the latest clinical developments in a wide range of tumor types.

science

All Episodes

13:46

Myelofibrosis Remains Tough to Treat, But New Drugs...

Oncology News Central Peer-Spectives ·

2022/11/11

Listen as Gabriela Hobbs, MD, clinical director of the leukemia atMass General, talks with Bob Figlin, MD, the Steven Spielberg Family Chair in Hematology Oncology at Cedars-Sinai Cancer in Los Angeles, about the latest progress in the treatment of myelofibrosisand how she both assesses new patients and plans their treatment. New agents, including JAK2 inhibitors,are not curative but can have substantial effects on patients and open up further treatment options. Dr. Hobbs also talks about new drug

en

14:12

KRAS Inhibition in NSCLC: When, How, and Why?

Oncology News Central Peer-Spectives ·

2022/11/11

Melissa Johnson, MD,a medical oncologist with Tennessee Oncology and Director of Lung Cancer Research at Sarah Cannon Research Institute in Nashville,joins host Robert Figlin, MD, Steven Spielberg Family Chair in HematologyOncologyat Cedars-Sinai Cancer, to talk about KRAS G12C inhibition in non-small cell lung cancer (NSCLC)treatment. She talks about how she uses sotorasib (Lumakras), which is U.S. Food and Drug Administration (FDA)approved for second-line treatment, why plasma-based genetic

en

14:07

Strategies for Navigating a Hematology/Oncology...

Oncology News Central Peer-Spectives ·

2022/11/04

The key steps to launching a successful and professionally fulfilling hematology/oncology fellowship is to “reflect, project, and adapt,” according to Gerald Hsu, MD, PhD, associate clinical professor of medicine and director of the Hematology/Oncology Fellowship Program at UCSF. Dr. Hsu spoke with Robert Figlin, MD, to discuss how new fellows can best navigate the opportunities they’re presented with. Dr. Hsu recommends reflecting on your areas of passion and interest, projecting what you’ll need

en

12:15

Taking Aim at MET and KRAS in NSCLC

Oncology News Central Peer-Spectives ·

2022/10/29

Tejas Patil, MD, assistant professor of medical oncology at the University of Colorado Cancer Center, talks with Robert A. Figlin, MD, about new targeted therapies for non-small cell lung cancer (NSCLC), particularly tepotinib (Tepmetko) for MET exon 14 and sotorasib (Lumakras) for KRAS G12C. The MET exon 14 skip mutation has attracted renewed attention because tepotinib and capmatinib (Tabrecta), which both target this mutation, recently received FDA approvals. But MET can be disrupted in other

en

12:36

Mantle Cell Lymphoma: Optimizing Current Therapies

Oncology News Central Peer-Spectives ·

2022/10/28

Jonathan Cohen, MD, MS, Associate Professor, Hematology and Medical Oncology, Emory University School of Medicine, , joins OBR Editor-in-Chief Robert Figlin, MD, to talk about mantle cell lymphoma. Dr. Cohen describes the key to making a correct diagnosis and what the best frontline treatment approaches are for different patient groups. He also talks about how BTK inhibitors and CAR T-cell therapy are shifting the treatment landscape and what he’s anticipating will be presented at upcoming

en

12:05

COSMIC-313 trial and the Complex Treatment Landscape...

Oncology News Central Peer-Spectives ·

2022/10/19

Bob Figlin, MD, and Toni Choueiri, MD, the director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, discuss the early results from the COSMIC-313 trial, which Dr. Choueiri presented at ESMO 2022. The trial enrolled previously untreated patients with metastatic clear cell renal cell cancer who were classified as intermediate- to poor-risk. Standard of care doublet therapy, nivolumab (nivo) plus ipilimumab (ipi), was compared with triplet therapy, consisting of nivo-ipi

en

14:52

Finding Joy in Work: ASCO’s Career Development...

Oncology News Central Peer-Spectives ·

2022/10/04

Bob Figlin, MD, and Jamie Von Roenn, MD, discuss strategies for learning about the oncology specialty earlier in the training pipeline, particularly for under-represented groups. They also look at opportunities for oncology fellows to build skills in different career areas.

en

17:54

Considering an Oncology Fellowship? Listen to This First

Oncology News Central Peer-Spectives ·

2022/09/06

Gerald Hsu, MD, PhD, UCSF’s hematology/oncology fellowship program director, joins Robert Figlin, MD, to talk about what fellowship programs are looking for in applicants, how trainees can find programs that are a good fit, and why preparing for an interview improves the odds you land at the right spot for you.

en

13:19

Kidney Cancer at a Crossroads: What New Trial Results...

Oncology News Central Peer-Spectives ·

2022/08/19

Michael B. Atkins, MD, and Robert Figlin, MD, discuss results from the EVEREST clinical trial as well as new data on TKIs, immunotherapy, and HIF-2 inhibitors. They also discuss adjuvant therapy and how depth of response differs between immunotherapy and TKIs, and look ahead to what the future holds.

en

11:15

How to Choose CLL Treatments in the Frontline Setting

Oncology News Central Peer-Spectives ·

2022/07/08

Danielle Brander, MD, talks with Robert Figlin, MD, about selecting frontline treatments for CLL and how she talks with patients about their treatment options. “What I think is unique about the last few years is we’ve seen multiple randomized trials in the frontline setting that have shown not only superior progression-free survival … but several of those randomized studies also showing improvement in overall survival versus chemoimmunotherapy,” Dr. Brander said. “I think it’s really important for

en

11:15

Rethinking HER2-Targeted Therapy After DESTINY-04

Oncology News Central Peer-Spectives ·

2022/07/07

William Gradishar, MD, talks with Robert Figlin, MD, about breast cancer research highlights from the 2022 American Society of Clinical Oncology Annual Meeting, including results from DESTINY-Breast04 and new data on CDK4/6 inhibitors from the PALOMA-2 and MAINTAIN trials.

en

12:44

Most Patients with BRAF-mutant Metastatic Melanoma...

Oncology News Central Peer-Spectives ·

2022/06/16

Michael B. Atkins, MD, talks with Robert A. Figlin, MD, about the importance of sequencing therapies for patients with BRAF-positive metastatic melanoma. Data from the DREAMSeq trial, which Dr Atkins updated at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, show a significant survival advantage at two years for patients who receive ipilimumab plus nivolumab prior to receiving a BRAF/MEK inhibitor. But not all patients fit that paradigm. Listen as Dr Atkins shares which

en

12:12

Adjuvant and Neoadjuvant Therapy for NSCLC: Who to...

Oncology News Central Peer-Spectives ·

2022/05/05

Listen in as Roy Herbst, MD, PhD, shares with Robert Figlin, MD, how he approaches treatment for patients with early-stage non-small cell lung cancer after the ADAURA and CHECKMATE-816 trials. They discuss different factors that influence use of adjuvant and neoadjuvant treatments, including stage, EGFR mutation status, and PD-L1 status.

en

13:07

The Complex Decisions in CLL Treatment Today:...

Oncology News Central Peer-Spectives ·

2022/04/13

Lori Leslie, MD, and Robert Figlin, MD, discuss the latest drugs and clinical trial data on CLL treatment. Dr. Leslie shares her strategy for sequencing agents, including various BTK inhibitors and venetoclax, and how she decides on treatment in patients whose disease progresses or are refractory.

en

11:12

DREAMseq Trial: What It Means for Metastatic Melanoma...

Oncology News Central Peer-Spectives ·

2022/03/29

Sapna Patel, MD, Associate Professor at MD Anderson Cancer Center, and Robert Figlin, MD, Deputy Director at Cedars-Sinai Cancer, discuss the clinical implications of the DREAMseq trial, showing patients with BRAF-mutant metastatic melanoma live longer if they receive first-line ipilimumab plus nivolumab.

en

21:35

The Latest Thinking Regarding Adjuvant Pembrolizumab...

Oncology News Central Peer-Spectives ·

2022/03/11

Rana McKay, MD, Allan Pantuck, MD, and Robert Figlin, MD, discuss the recent update to the Keynote-564 study investigating adjuvant pembrolizumab in RCC and the impact on high-, medium-, and low-risk patients. They also talk about the Disease-Free Survival (DFS) endpoint, discussing the study with patients, and the recent NCCN guidelines update.

en

09:41

Post ASCO GU ’22 – Muscle-Invasive Bladder Cancer,...

Oncology News Central Peer-Spectives ·

2022/03/07

Daniel Petrylak, MD, Professor of Medicine at the Yale Cancer Center, and Robert Figlin, MD, of Cedars-Sinai Cancer discuss recent developments at ASCO GU in muscle-invasive bladder cancer and in particular the EV-103 clinical study while also discussing the future of MIBC treatment.

en

10:35

The HIMALAYA Study Presented at ASCO GI ’22: An...

Oncology News Central Peer-Spectives ·

2022/01/26

Ghassan Abou-Alfa, MD and Robert Figlin, MD, discuss the presentation of the HIMLAYA clinical study at ASCO GI ’22 and how this regimen may fit in the liver cancer treatment landscape

en

11:06

Frederick Locke, MD of Moffit Cancer Center and...

Oncology News Central Peer-Spectives ·

2021/12/22

Frederick Locke, MD and Robert Figlin, MD discuss ZUMA-7 and when to start thinking about integrating CAR-T into B-cell lymphoma treatment algorithms, the role of BMT in these patients, and how recent data presented at ASH ’21 shows that CAR-T cell therapies can work well in relapsed/refractory B-cell lymphoma.

en

11:16

From SABCS ’21: Neoadjuvant Immunotherapy and the Use...

Oncology News Central Peer-Spectives ·

2021/12/14

Lajos Pusztai, MD, and Robert Figlin, MD, discuss the practicality of neoadjuvant I-O as demonstrated in KEYNOTE-522 and the application of the Oncotype DX 21-gene signature test in the RxPONDER study, both presented at the 2021 San Antonio Breast Cancer Symposium.

en

134 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter